High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 3, 2008, Pages 259-265

  Hörnfeldt, Erika ^a   Gjertsen, Henrik ^a   Weiland, Ola ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN A; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PREDNISOLONE; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; COUGHING; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MONOTHERAPY; MYALGIA; NEUTROPENIA; PATIENT COMPLIANCE; PRIMARY BILIARY CIRRHOSIS; PRURITUS; RECURRENT INFECTION; SKIN DISEASE; SLEEP DISORDER; THROMBOCYTOPENIA; VIROLOGY;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; VIRAL LOAD;

EID: 39349088307     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701633020     Document Type: Article

References (27)

1. Terrault, NA and Berenguer, M. (2006) Treating hepatitis C infection in liver transplant recipients. Liver Transpl, 12, pp. 1192-1204.
2. Gjertsen, H., Weiland, O., Oksanen, A., Soderdahl, G., Broome, U. and Ericzon, BG. (2006) Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm. Transplant Proc, 38, pp. 2675-2676.
3. Gish, RG, Afdhal, NH, Dieterich, DT and Reddy, KR. (2005) Management of hepatitis C virus in special populations: Patient and treatment considerations. Clin Gastroenterol Hepatol, 3, pp. 311-318.
4. Alter, HJ and Seeff, LB. (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis, 20, pp. 17-35.
5. Berenguer, M., Prieto, M., Rayon, JM, Mora, J., Pastor, M. and Ortiz, V. (2000) Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology, 32, pp. 852-858.
6. Fried, MW, Shiffman, ML, Reddy, KR, Smith, C., Marinos, G. and Goncales Jr, FL (2002) Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347, pp. 975-982.
7. Hadziyannis, SJ, Sette Jr, H., Morgan, TR, Balan, V., Diago, M. and Marcellin, P. (2004) Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med, 140, pp. 346-355.
8. Manns, MP, McHutchison, JG, Gordon, SC, Rustgi, VK, Shiffman, M. and Reindollar, R. (2001) Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet, 358, pp. 958-965.
9. Berenguer, M., Palau, A., Fernandez, A., Benlloch, S., Aguilera, V. and Prieto, M. (2006) Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl, 12, pp. 1067-1076.
10. Samuel, D. (2005) Antiviral treatment of recurrent hepatitis C after liver transplantation: The need for a multifaceted approach. Hepatology, 41, pp. 436-438.
11. Samuel, D., Bizollon, T., Feray, C., Roche, B., Ahmed, SN and Lemonnier, C. (2003) Interferon alpha-2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology, 124, pp. 642-650.
12. Burton Jr, JR and Rosen, HR. (2006) Treatment of HCV recurrence: Do the pretransplantation rules apply?. Liver Transpl, 12, pp. 1044-1048.
13. Reddy, KR, Shiffman, ML, Morgan, TR, Zeuzem, S., Hadziyannis, S. and Hamzeh, FM (2007) Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alpha-2a/ribavirin treatment. Clin Gastroenterol Hepatol, 5, pp. 124-129.
14. Bronowicki, JP, Ouzan, D., Asselah, T., Desmorat, H., Zarski, JP and Foucher, J. (2006) Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2a plus ribavirin. Gastroenterology, 131, pp. 1040-1048.
15. Pawlotsky, JM, Dahari, H., Neumann, AU, Hezode, C., Germanidis, G. and Lonjon, I. (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology, 126, pp. 703-714.
16. Neumann, AU, Lam, NP, Dahari, H., Gretch, DR, Wiley, TE and Layden, TJ (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282, pp. 103-107.
17. Pawlotsky, JM, Bouvier-Alias, M., Hezode, C., Darthuy, F., Remire, J. and Dhumeaux, D. (2000) Standardization of hepatitis C virus RNA quantification. Hepatology, 32, pp. 654-659.
18. Doglio, A., Laffont, C., Caroli-Bosc, FX, Rochet, P. and Lefebvre, J. (1999) Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol, 37, pp. 1567-1569.
19. Stuyver, L., Wyseur, A., van Arnhem, W., Hernandez, F. and Maertens, G. (1996) Second generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol, 34, pp. 2259-2266.
20. Yun, Z., Lara, C., Johansson, B., de Rivera, I Lorenzana and Sonnerborg, A. (1996) Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol, 49, pp. 155-160.
21. Batts, KP and Ludwig, J. (1995) Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol, 19, pp. 1409-1417.
22. Schvarcz, R., Glaumann, H., Reichard, O. and Weiland, O. (1999) Histological and virological long- term outcome in patients treated with interferon alpha-2b and ribavirin for chronic hepatitis C. J Viral Hepat, 6, pp. 237-242.
23. Mangia, A., Santoro, R., Minerva, N., Ricci, GL, Carretta, V. and Persico, M. (2005) Peginterferon alpha-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med, 352, pp. 2609-2617.
24. Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y. and Cianciara, J. (2006) Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viraemia. J Hepatol, 44, pp. 97-103.
25. Dumortier, J., Ducos, E., Scoazec, JY, Chevallier, P., Boillot, O. and Gagnieu, MC. (2006) Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat, 13, pp. 538-543.
26. Lindahl, K., Schvarcz, R., Bruchfeld, A. and Stahle, L. (2004) Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat, 11, pp. 84-87.
27. Berg, T., Von Wagner, M., Nasser, S., Sarrazin, C., Heintges, T. and Gerlach, T. (2006) Extended treatment duration for hepatitis C virus type 1: Comparing 48 vs 72 weeks of peginterferon alpha-2a plus ribavirin. Gastroenterology, 130, pp. 1086-1097.